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Introduction
Management of patients with acute myocardial infarction rep-
resents a great challenge to emergency physicians, a task more recently
complicated by the myriad of potential treatment options available.  The
goal of reperfusion therapy in patients with ST segment elevation myo-
cardial infarction (STEMI) is the safest, earliest and most complete res-
toration of normal (TIMI-3) flow in the infarct related artery.   Current
strategies include thrombolysis, primary angioplasty or a combination of
the two.  Recent advances in antiplatelet and antithrombotic therapy
with glycoprotein IIB / IIIA inhibitors and low molecular weight heparins
have introduced another option, multimodal combination pharmacologi-
cal therapy.1,2
Multiple clinical trials which included thousands of patients
undergoing thrombolytic therapy for STEMI have demonstrated a sub-
stantial improvement in mortality with their use.3  The principle determi-
nants of survival after reperfusion therapy are speed of reperfusion and
the magnitude of patency restoration.  Retrospective analysis by
Tiefenbrunn and Boersma of data from more than 20 clinical trials dem-
onstrates a clear time dependant benefit from reperfusion therapy.4,5  In
both models, the benefit / time curve is very steep until approx 2 hours
after symptom onset, suggesting the greatest benefit was achieved early,
with more modest results occurring between 2 and 12 hours after symp-
tom onset.  Therapy after 12 hours from symptom onset is generally
regarded as not beneficial.3    Likewise, this time dependent benefit has
been shown in trials where primary angioplasty was performed.  In the
Gusto IIB cohort of 1,138 patients with acute myocardial infarction, 565
patients underwent primary angioplasty.6  The primary endpoint was
thirty-day mortality, which in patients treated within 60 minutes of
presentation was 1%.  A consistent decline in mortality benefit was seen
with increasing door to balloon times.  The mortality in patients treated
after 90 minutes was 6.4%.  In addition, data from more than 27,000
patients enrolled in the National Registry of Myocardial Infarction
(NRMI-2), an industry sponsored observational registry of patients with
acute myocardial infarction, showed a nearly 50% increase in mortality if
more than 2 hours elapsed from arrival to balloon inflation.7
The impact of complete restoration of patency is equally im-
portant to clinical outcome and is part in parcel to the goal of therapy -
early and full reperfusion.8  Gibson’s analysis of angiographic data from
nearly 5,500 patients enrolled in fibrinolytic trials shows a clear relation-
ship between 90-minute patency and mortality.9  Short-term mortality
(4-6weeks) in patients with TIMI-3 flow (3.7%) was significantly lower
than in patients with TIMI-2 flow ( 6.1 %, p < 0.001) and TIMI-0/1 flow
(9.3%, p < 0.001).  Furthermore, recent data suggests that while epicar-
dial blood flow is paramount, perfusion at the tissue level or microcir-
culation of the myocardium may be equally or more important.10  TIMI
myocardial perfusion grading is a new angiographic method for assess-
ing the microcirculation.  This technique allows additional risk stratifi-
cation within the TIMI epicardial grade flow.  In data taken from the
TIMI 10B trial, myocardial perfusion was an independent predictor of
mortality regardless of epicardial TIMI grade flow.11  However, there is
a synergistic effect between epicardial blood flow and microvascular
perfusion and their relationship to mortality, the higher the flow /
perfusion the lower the mortality.  This finding has generated signifi-
cant enthusiasm in the arena of combining thrombolytics with glyco-
protein IIB/IIIA inhibitors as the latter is postulated to have a benefi-
cial effect on the microcirculation.
Thrombolytics -vs- Primary Angioplasty
As one can probably surmise, the principal determinants of
survival are not equally inherent to these two treatment strategies.
Outlining the advantages and disadvantages of each strategy will help
shed some light on the controversy faced by emergency physicians and
cardiologist in determining the best treatments for their patients.
Thrombolytic therapy has a wealth of supporting clinical
trial data which demonstrates a proven mortality benefit.3,12  It’s ease
of use, rapid administration, and universal availability have made it the
historical gold standard of reperfusion therapy.  It requires no special-
ized equipment or personnel and is essentially available in any emer-
gency setting.  Unfortunately, this universal agent comes with a price,
most notably bleeding complications.  The most feared is intracranial
hemorrhage or stroke which occurs in approximately 1% of treated
patients.3,12  In addition, the risk of intracranial hemorrhage increases
with advancing age.  There are also numerous contraindications related
to bleeding risk which limits its use in certain patients.  Although the
speed of patency restoration for thrombolytic therapy is excellent, it’s
extent is not.  Only 50-60% of patients achieve TIMI-3 flow at 90
minutes.8  Further, many patients have subsequent reocclusion and
recurrent infarction, likely as a result of paradoxical activation of the
coagulation cascade.  This prothrombotic effect has prompted investi-
gators to look at alternate pharmacologic strategies such as a combina-
tion of thrombolytics with glycoprotein IIB / IIIA inhibitors to poten-
tially attenuate this effect. 1,2
Strategies for reperfusion employing primary angioplasty
have been gaining momentum in the last decade, encouraged by clinical
trials and meta-analysis suggesting its superiority over thrombolytic
therapy  13,14,15 as well as interventional cardiologist enthusiasm for
performing the procedure.  This strategy’s main attributes are superior
patency of the infarct related artery (90% TIMI-3 flow at 90 minutes)
and low risk of bleeding complication, especially intracranial hemor-
rhage.16  There are few contraindications and it provides the physician
with immediate knowledge of the coronary anatomy.  This may afford
further risk stratification and in some cases of diagnostic uncertainty,
may provide the definitive diagnosis.  Additionally, primary angioplasty
is the preferred strategy in patients with cardiogenic shock, those with
acute myocardial infarction and persistent symptoms beyond 12 hours
and those who fail to reperfuse with thrombolytic therapy.17
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As was the case with thrombolytic therapy, not everything
about primary angioplasty is positive.  Its greatest detractor is its
limited availability and inherent delay in mobilizing a catheterization
laboratory team. In order to perform primary angioplasty the hospital
must have a catheterization laboratory and skilled personnel readily
available.  This is the case in fewer than 20% of US hospitals. 18
Furthermore, the ACC/ AHA guidelines recommend that primary
angioplasty be performed at high volume centers that perform more
than 200 procedures per year and by individual operators who perform
more than 75 procedures per year.17  Thus, only a small fraction of
hospitals have facilities and skilled personnel with enough experience
to be proficient at this procedure.  This requirement may dilute some of
the robust findings of earlier trials of primary angioplasty.13    Specifi-
cally, the results may only be reproducible in specialized centers geared
up for primary angioplasty 24 hours a day, not in hospitals typically
found in the community setting.
Studies Comparing Primary Angioplasty and Thrombolysis
A number of trials have been performed which directly com-
pare primary angioplasty with thrombolysis.  Unfortunately, they all
have relatively small sample size and utilize either different throm-
bolytic agents or varying doses.  Most of the trials were also performed
at specialized centers that perform angioplasty routinely.  Nonethe-
less, several authors have performed meta-analysis of these trials in an
attempt to determine if one strategy is superior.
 In an overview by Michels et.al. the authors reviewed seven
trials comprising 1,145 patients with STEMI who were treated with
either primary angioplasty or thrombolysis (streptokinase or
alteplase).13  Those undergoing primary angioplasty had a considerable
reduction in short term  (= 6 weeks) mortality (OR .56, 95% CI .33-
.94).  There was no longterm follow up data for mortality comparisons.
A review by Weaver et. al.14 of 10 trials totaling 2,606 patients included
the relatively larger PAMI19 and Gusto IIB cohorts.6  Primary
angioplasty was compared to thrombolytic therapy in which 4 trials
utilized strepokinase, 3 used accelerated alteplase and 3 used standard
dose alteplase.  Comparing primary angioplasty to thrombolytics at 30
days, mortality was 4.4% vs. 6.5%  (OR .66, 95% CI .46-.94), death or
reinfarction was 7.2% vs. 11.9% (OR .58, 95% CI .44-.76), and the rate
of hemorrhagic stroke was 0.1%vs1.1% (OR .07, 95% CI 0-.43).  The
results were similar among the varying thrombolytic agents.  Again
there was insufficient long-term data available for meaningful compari-
sons but 6 month follow-up data from Gusto IIB, which comprised
nearly half the patients, showed significant attenuation of the short-
term benefits ascribed to primary angioplasty.6
The Cochrane database reviewed 10 trials with a total of
2,573 patients, many of whom were included in the previous review.15
Similar to earlier findings, primary angioplasty was associated with
significant relative risk reduction in short term mortality (RRR 32%,
95% CI 5-50%), death or reinfarction (RRR 46%, 95% CI 30-58%) and
stroke (RRR 66%, 95% CI  28-84%).  Interestingly, in a subgroup
analysis the authors compared results from the largest and most recent
study, Gusto IIB, to the pooled analysis.  The results from Gusto IIB
were less impressive than the pooled data, suggesting that the mortal-
ity benefit of primary angioplasty is less impressive when performed
in community hospitals, as was the case in Gusto IIB.  Another pos-
sible explanation is the use of non-optimal thrombolytic therapy (strep-
tokinase  or standard dose alteplase) in the other pooled trials vs.
accelerated alteplase that was used in Gusto IIB.
Emergency physicians should be cautious about comparing re-
sults found in clinical trials performed in highly specialized centers to
their “real world” clinical practice.  Observational registries, although
not true clinical trials, may provide important information about the
typical clinical practice and can be used to counterbalance the poten-
tially unrealistic findings of the aforementioned clinical trials.
Every et. al. looked at data from the Myocardial Infarction
Triage and Intervention (MITI) registry comparing 1,050 patients
who underwent primary angioplasty with 2,095 patients undergoing
thrombolytic therapy (2/3 alteplase, 1/3 streptokinase) and found no
difference in mortality out to 4 years.20  Data from nearly 30,000
patients in NRMI-2 showed similar results.21 The authors compared
4,939 patients undergoing primary angioplasty with 24,705 patients
undergoing thrombolytic therapy (92% accelerated alteplase).  For
patients not in cardiogenic shock, in hospital mortality was similar for
both groups, 5.2% vs 5.4% as was death/non-fatal stroke, 5.6% vs
6.2%.  On the contrary, patients who were in cardiogenic shock had
significantly lower in hospital mortality in the primary angioplasty
group than the thrombolytic group (32.4% vs. 52.3%, p<0.0001).
Summary
Selecting the ideal reperfusion strategy is a daunting task for
emergency physicians as is interpreting the many confusing and con-
flicting reports comparing thrombolytic therapy to primary
angioplasty.  Thrombolytic therapy offers universal availability and is
easy to use but suffers from only modest reperfusion rates and inher-
ent bleeding risk.  On the other hand, primary angioplasty offers
superb reperfusion rates and minimal bleeding complications but is
hampered by excessive time delays and lack of availability.  From the
current data, primary angioplasty appears to be therapeutically more
advantageous but only if readily available and performed by experi-
enced physicians.
The ultimate decision should incorporate a strategy that
provides the safest and most efficacious reperfusion in your setting.
For most physicians this will be dependent upon their institutions
ability and desire to provide specialized equipment and personnel
needed to perform primary angioplasty.
Most importantly for the emergency physician is to be
prepared.  Decisions about preferred strategies should be made well
ahead of time, not at the patient’s bedside.  In order to be effective and
timely with either strategy you should have a protocol or critical
pathway that outlines the decision making process as well as the steps
for actual implementation of therapy.  The debate over the best strat-
egy will continue in the foreseeable future as multiple trials employing
various combinations of pharmacologic agents and mechanical
reperfusion have been recently completed or are underway.  The re-
sults of these studies will dictate the future direction of reperfusion
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Because of the recent terrorist attacks in the United States
there has been an increasing need for health care practitioners to have
a fundamental knowledge in the agents of bioterrorism.  Unlike tradi-
tional acts of overt terrorism, bioterrorism is covert.  This means the
effects of the attack will first be identified in the emergency depart-
ment.  This new threat, as evidenced by the recent exposures to
anthrax, has illustrated the importance of physicians in diagnosing,
treating, and educating patients on bioterrorism.  The goal of this
article is to set a framework for understanding the most important
agents as designated by the CDC.
The CDC has categorized the many agents of bioterrorism into
categories A, B, and C.  The A agents are felt to be the easiest to
disseminate, cause the highest mortality, and require special prepared-
ness.  B agents are felt to be second in priority, and C agents are
emerging pathogens.1  Category A agents include: smallpox, anthrax,
botulism, tularemia, and viral hemorrhagic fever.  Category B agents
include: Q fever, brucellosis, glanders, alphivirus, and various food
and waterborn pathogens. Category C agents are considered emerging
and include: nipah virus, hantavirus, tick borne hemorrhagic fever,
yellow fever, and multidrug resistant TB.  The focus of this article is
to review the various aspects of category A agents deemed important
for the recognition of a bioterrorist threat.
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